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Breast cancerIt has been demonstrated that miR-874 plays important roles in many types of cancers.
Nevertheless, its biological function in breast cancer remains largely unknown. In this study, we
found that the expression level of miR-874 is down-regulated in breast cancer in comparison with
the adjacent normal tissues. The overexpression of miR-874 is able to inhibit cell proliferation and
induce cell apoptosis and cell cycle arrest in MCF7 and MDA-MB-231 cells. Using a bioinformatics
method, we further show that CDK9 is a direct target of miR-874 and that its protein level is
negatively regulated by miR-874. Therefore, the data reported in this manuscript demonstrate that
miR-874 is an important regulator in breast cancer and imply that the miR-874/CDK9 axis has
potential as a therapeutic target for breast cancer.
 2014 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Breast cancer is the most common cancer in women around the
world, which can be influenced by a number of environmental
factors and is characterized by molecular heterogeneity [1].
Despite various existing screening programs and new therapeutic
strategies have been implemented to treat breast cancer and
significantly reduced mortality rates, the molecular mechanisms
underlying breast cancer pathogenesis are only partially under-
stood [2]. MicroRNAs (miRNA) are 19–25 nucleotide non-coding
RNAs and have critical role in cancer progression through either
protein translation repression or mRNA degradation to regulate
their target mRNAs [3]. It has been shown that miRNAs serve as
oncogenes or tumor suppressor genes to control cell proliferation,
invasion, migration, differentiation and apoptosis [4–6]. With
deregulated expression in several cancers including breast cancer,
miRNAs are evolving as potential diagnostic and therapeutic mark-
ers [7]. Recently, the tumor suppressive role of miR-874 by inhibi-
tion of cell proliferation and invasion was reported in gastriccancer [8]. It has been demonstrated that miR-874 can inhibit
NSCLC-initiating cells invasion and migration via directly regulat-
ing the protein expression of MMP-2 and uPA in vitro and in vivo
[9]. Nohata et al. [10] found that comparing with adjacent normal
epithelia, the expression levels of miR-874 were significantly
downregulated in HNSCC (head and neck squamous cell carci-
noma) tissues. Furthermore, the overexpression of miR-874 in
HNSCC cell lines (SAS and FaDu) revealed that miR-874 can directly
target HDAC1 (histone deacetylase 1) to inhibit cell proliferation
and induce cell apoptosis. In another study conducted in maxillary
sinus squamous cell carcinoma (MSSCC), miR-874 was found
downregulated in MSSCC specimens and PPP1CA (protein phos-
phatase 1, catalytic subunit, a isozyme) was identified as a direct
target of miR-874 [11]. Cyclin-dependent kinase 9 (CDK9), a mem-
ber of the cdc2-like serine/threonine kinase family, interacts with
specific types of cyclins to exert its biological activity [12,13]. This
interaction forms a heterodimer, in which the Cdk serves as cata-
lytic domain, and the cyclin partner, T cyclins (T1, T2a and T2b)
and cyclin K, functions as the regulatory subunit [14,15]. It has
been described that a number of human malignancies occur dere-
gulations of the CDK9-related pathway, such as lymphomas [16],
neuroblastoma [17], primary neuroectodermal tumor [18], rhabdo-
myosarcoma [19], and prostate cancer [20].
In the present study, the role of miR-874 and CDK9 in breast
cancer tissues and cells was investigated. Our findings verified that
4528 L. Wang et al. / FEBS Letters 588 (2014) 4527–4535the expression of miR-874 was downregulated, while CDK9 was
upregulated in the breast cancer tissues compared with adjacent
normal tissues. Overexpression of miR-874 can lead to suppressing
of breast cancer cells growth, colony formation, cell cycle and
increasing of cell apoptosis. Furthermore, we experimentally
validated that miR-874 can directly target the 30UTR of CDK9 and
suppress its expression. Finally, we determined that knockdown
of CDK9 can promote apoptosis and induced cell cycle arrest in
breast cancer cells. Therefore, our results demonstrated that
miR-874 can mediate its tumor suppressor function, at least in
part, by suppressing the expression of CDK9. Altogether, our study
characterized a novel microRNA-mediated mechanism of CDK9
regulation and suggests tumor inhibiting actions of miR-874 in
breast cancer cells.
2. Materials and methods
2.1. Patient samples
Breast cancer specimens and adjacent normal tissues were col-
lected in the First Affiliated Hospital of Nanjing Medical University
(Nanjing, China) from January 2011 to December 2013. All the
patients recruited into the present study did not receive radiother-
apy, chemotherapy or any other treatment before and after opera-
tion. Surgical specimens of the tumor resection were collected, and
lumps of tumors as well as adjacent normal tissues, which were at
least 2 cm distal to tumor margins, were snap-frozen in liquid
nitrogen for miR-874 and CDK9 assays. Written informed consent
was obtained from all the study participants. The use of tissue
samples were approved by the ethical committees of the ethical
committees of the First Affiliated Hospital of Nanjing Medical
University. The detailed patient information is shown in Table 1.
2.2. Cell culture and transfection
Two widely used cell lines, a more aggressive breast cancer cell
line (MDA-MB-231) and a less aggressive breast cancer cell line
(MCF-7) were used in this study, which were obtained from theTable 1
Breast cancer patient clinical information.
Index Gender Age Clinical diagnosis (TNM stage)
1 Female 35 T1N0M0
2 Female 65 T2N1M0
3 Female 56 T1N0M0
4 Female 60 T3N1M0
5 Female 75 T1N0M1
6 Female 55 T1N0M1
7 Female 51 T2N1M0
8 Female 46 T3N0M0
9 Female 67 T3N0M1
10 Female 65 T1N0M0
11 Female 46 T1N0M0
12 Female 62 T3N0M1
13 Female 37 T1N0M0
14 Female 59 T1N0M0
15 Female 38 T1N0M0
16 Female 62 T3N1M1
17 Female 40 T3N0M0
18 Female 38 T1N0M0
19 Female 65 T2N1M0
20 Female 77 T1N0M0
21 Female 72 T2N1M1
22 Female 67 T1N3M1
23 Female 61 T3N0M0
24 Female 68 T1N0M0
25 Female 59 T3N2M1
26 Female 42 T1N0M0ATCC and maintained in RPMI 1640 with 10% fetal bovine serum
(FBS) and 1% antibiotics (Invitrogen, USA). Transfection of the cells
with miR-874 mimics or miR-Control (Genepharma, China) was
performed using Lipofectamine 2000 (Invitrogen, USA) according
to the manufacturer’s instructions. The transfected amount of
miR-874 mimics and miR-Control was 10 pmol per 1  103 cells.
2.3. Detection of cell phenotypes
The effect of miR-874 on proliferation of breast cancer cells was
evaluated by the MTT assay. MCF-7 and MDA-MB-231 cells were
plated in 96-well culture plates (3  103 per well). After 24 h incu-
bation, the cells were transfected with miR-874 mimics (30 pmol)
or miR-Control (30 pmol) for 12, 24 and 48 h. Then the MTT
(0.5 mg/ml; Sigma–Aldrich, USA) was added to each well (20 ll/
well). After 4 h of additional incubation, MTT solution was dis-
carded and 200 ml of DMSO (Sigma, USA) was added, and the
plates were shaken gently. The absorbance was measured on an
ELISA reader at a wavelength of 570 nm. For the colony formation
assay, cells were counted and seeded in 12-well plates (in tripli-
cate) at 100 cells per well. Fresh culture medium was replaced
every three days. The number of viable cell colonies was deter-
mined after 14 days, and the colonies were fixed with methanol,
stained with crystal violet, photographed and counted. Each
experiment was performed in triplicate.
2.4. Cell cycle and apoptosis assays
The transfected MCF-7 and MDA-MB-231 cells were seeded into
six-well plates for 24 h in complete medium. Then, the cells were
deprived of serum for 48 h followed by returning complete
medium for an additional 24 h. After that, the cells were collected
by centrifugation, fixed in 95% ethanol, incubated at 20 C
overnight and washed with phosphate buffered saline (PBS). The
cells were then resuspended in 1 ml of FACS solution (PBS, 0.1%
TritonX-100, 60 lg/ml propidium iodide (PI), 0.1 mg/ml DNase free
RNase, and 0.1% trisodium citrate) with final incubation on ice for
30 min. The cells were analyzed using a FACSCalibur flow cytome-
ter (Beckman Coulter). A total of 10000 events were counted for
each sample. For the Annexin V assay, the MCF-7 and MDA-MB-
231 cells were transfected. After 48 h, the DNA content was deter-
mined by propidium iodide staining as described by Hwang et al.
[21], and Annexin V staining was performed with the Vybrant
Apoptosis Assay Kit (Invitrogen).
2.5. Western blotting
Western blotting was performed to determine protein expres-
sion of CDK9. The total protein was extracted by TRIzol reagent
(Invitrogen, USA) and the protein concentration in the superna-
tants were determined using Bradford protein dye reagent (Bio-
Rad, Hercules, CA), and the volumes of the supernatants were then
adjusted for equal protein concentration in all of the samples.
Immunoblotting was performed as described previously [22]. Anti-
bodies specific to CDK9 and GAPDH were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA).
2.6. RT-PCR
The RNAs were extracted using TRIzol reagent (Invitrogen,
Carlsbad, CA) and reverse-transcribed using gene-specific reverse
primers and reverse transcriptase (Takara, Japan), and the resulting
cDNAs were PCR-amplified on an ABI 7500 thermocycler (Applied
Biosystems). For the detection of miR-874, the following primers
were used: miR-874, qRT-PCR stem-loop primer, 50-GTCGTATCCAG
TGCAGGGTCCGAGGTATTCGCACTGGATACGACTCTTAGG-30, Qpcr
Fig. 1. Expression of miR-874 in breast cancer tissues. (A) The relative expression of miR-874 (normalized to U6) was detected using qRT-PCR in breast cancer tissues and
matched adjacent normal tissues; (B) Relative expression of miR-874 in well- and moderately differentiation tissues as well as tissues with poor or no differentiation; (C)
Relative expression of miR-874 in tumor size less than 5 cm and tumor sizes greater than 5 cm.
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primer, 50-CCAGTGCAGGGTCCGAGGT-30; U6, Qrt-pcr stem-loop
primer, 50-GTCGTATCCAGTGCAGGGTCCGAGGTGCACTGGATACGA
CAAAATATGG-30, qPCR forward primer, 50-TGCGGGTGCTCG
CTTCGGCAGC-30, reverse primer qPCR, 50-CCAGTGCAGGGTCC
GAGGT-30. U6 was used to standardize the amounts of miRNAs in
each samples.
2.7. Construction of 30UTR reporter plasmid and luciferase assay
The human CDK9 30UTR harboring miR-874 target sequence as
well as the seed-sequence-mutated version (miR-874–30UTR-mut)
were synthesized by GenPharm (Shanghai, China). The CDK9 30UTR
reporter was generated by inserting the entire 30UTR or 30UTR-mut
of human CDK9 mRNA into XhoI/NotI sites of psiCHECK-2 vector(Promega) downstream of the Renilla luciferase gene. For the
luciferase assay, 1  105 cells were transfected with the CDK9
30UTR reporter and the miR-874 mimics in a 24-well plate
using LipofectamineTM 2000 (Invitrogen) according to the manufac-
turer’s protocol. After 24 h, the firefly and Renilla luciferase activi-
ties were measured consecutively using Dual Luciferase Assay
(Promega).
2.8. Knockdown of CDK9 by siRNA
The transient transfection of CDK9 siRNA was performed using
LipofectamineTM 2000 (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s directions. After 48–72 h, the cells were
analyzed to determine the effects of the knockdown. The
silencing efficiency was confirmed by western blot. The siRNA
Fig. 2. miR-874 inhibits the proliferation of breast cancer cells. (A) QRT-PCR was used to detect the transfection efficiency of miR-874 mimics in MCF-7 and MDA-MB-231
cells; (B and C) Cell survival was determined by the MTT assay; (D and E) The long term cell growth as determined by colony formation assay; [3] (F) Tumor volume
remarkably decreased after miR-874 mimics administration compared to the control group.
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(sc-29268 添 加 公 司, 货 号).
2.9. Tumorigenicity in vivo
The lentiviral vector that overexpresses pre-miR-874 and the
control lentiviral packaging plasmid was purchased from Gene-
chem (Genechem, Shanghai, China). A total of sixteen nude mice
(BALB/c nude mice, Vital-river, Nanjing, China; 4 weeks old) were
randomly divided into two groups. MCF-7 cells stably transfected
with pre-miR-874 mimics and pre-miR-Control were inoculated
bilaterally and subcutaneously into the flanks of nude mice. Bidi-
mensional tumor measurements were taken with vernier calipers
every seven days, and the mice were euthanized after four weeks.
The volume of the implanted tumor was calculated using the for-
mula: volume = (width2  length)/2.
2.10. Statistical analysis
A Student0s test was performed to analyze the significance of
differences between the sample means obtained from three inde-
pendent experiments. Differences were considered statistically sig-
nificant at P < 0.05.
3. Results
3.1. Relative expression of miR-874 in breast cancer tissue
In this study, the expression levels of miR-874 was measured
with qRT-PCR in 26 pairs of breast cancer tissues and adjacent nor-
mal tissues, which showed that miR-874 was downregulated in thebreast cancer tissues (Fig. 1A). In addition, we showed that miR-
874 expression was associated with pathological differentiation
and tumor size in breast cancer tissues. As shown in Fig. 1B, the
expression of miR-874 were down-regulated in breast cancer tissues
with poor or no differentiation compared with well and moderate
differentiation tissues. Furthermore, lower expression of miR-874
in breast cancer tissues with tumor size greater than 5 cm compared
with tissues with tumor size less than 5 cm (Fig. 1C).
3.2. miR-874 suppresses breast cancer proliferation in vitro and in vivo
To investigate the function of miR-874 in the breast cancer cells
lines, MCF-7 and MDA-MB-231 were transfected with miR-874
mimics. As shown in Fig. 2A, miR-874 mimics increased the
expression of miR-874 by 17-fold and 16-fold in MCF-7 and
MDA-MB-231 cells, respectively. Growth curve and MTT assays
were performed to detect the effects of miR-874 on cell growth
in vitro. Our data demonstrated that the relative cell growth was
significantly inhibited in the miR-874 mimics transfected cells
(Fig. 2B–D). As shown in Fig. 2E, our data showed that the cell
apoptosis was induced obviously in miR-874 mimics transfected
MCF-7 and MDA-MB-231 cells. To assess the effect of miR-874
on tumorigenicity in vivo, we packaged recombinant lentivirus
producing the miR-874 precursor and infected the MCF-7 cells.
The transfected cells were injected into a flank of nude mice to
form ectopic tumors. Cells transfected with negative lentiviral vec-
tor was used as negative control and inoculated into the opposite
flank of the same mice. Notably, miR-874 over-expression signifi-
cantly suppressed tumorigenicity in a time dependent manner
in vivo, where the tumor size was dramatically decreased com-
pared with that of the controls (Fig. 2F).
Fig. 3. miR-874 induces cell apoptosis and cell cycle arrest. (A and B) TUNEL-TMR staining was used to detect DNA fragmentation during programmed cell death in MCF-7
and MDA-MB-231 cells transfected with miR-874 mimics or miR-control; (C and D) FACS analysis was used to detect the effect of miR-874 on the cell cycle of MCF-7 and
MDA-MB-231 cells.
L. Wang et al. / FEBS Letters 588 (2014) 4527–4535 45313.3. miR-874 induces apoptosis and inhibits cell cycle in breast cancer
cell lines
To address the mechanism underlying miR-874-modulated cell
growth, TUNEL-TMR staining was used to detect the effect of miR-
874 on cell apoptosis. The proportion of apoptotic MCF-7 cells trans-
fected with miR-874 was significantly higher than the miR-control
group Fig. 3A and B, 11.5% vs 21.6%). In the MDA-MB-231 cells, we
also detected an increased percentage of apoptotic cells compared
with that of miR-control group (Fig. 3A and B, 17.8% vs 23.3%). More-
over, cell cycle arrest was observed in miR-874 transfected MCF-7
and MDA-MB-231 cells via increasing the percentage of cells in G0/
G1 phase and reducing the cell population in S phase (Fig. 3C and D).
3.4. miR-874 directly targets and inhibits CDK9 protein expression
To explore the potential target of miR-874, five computational
algorithms, namely DIANA, miRDB, TargetScan, miRwalk and miR-
anda, were used and a set of different target genes were predicted.
Among these candidate targets, CDK9 attracted our attention
immediately which was predicted by all five algorithms (Fig. 4A).
Moreover, we found out that the binding of miR-874 with CDK9
seed sequence had a minimum free energy (mfe) of 25.7 kcal/
mol, suggesting that the binding of miR-874 with CDK9 may form
a stable structure. To investigate whether miR-874 can directly
target CDK9, the 30UTR luciferase reporter assay was performed,
which showed the miR-874 had an obvious inhibitory effect on
the luciferase intensity of wild-type 30UTR luciferase reporter.
However, the inhibitory effect of miR-874 was reduced in the
presence of mutant 30UTR luciferase reporter (Fig. 4C). We thentested whether miR-874 can affect the expression of endogenous
CDK9. The restoration of the miR-874 expression resulted in a
reduction of endogenous CDK9 protein expression in MCF-7 and
MDA-MB-231 cells, while miR-874 had no effect on the CDK9
RNA level (Fig. 4D). These results provide evidence that miR-874
can directly target the 30UTR of CDK9 mRNA, resulting CDK9 trans-
lation inhibition and suppressing its expression.
3.5. The expression of CDK9 in breast cancer tissues
Since we have demonstrated the expression levels of CDK9 in
breast cancer cell lines and tissues, qRT-PCR was used to measure
the mRNA expression levels of CDK9 in the 20 pairs breast cancer
tissues and adjacent normal tissues (ANT). Compared with the
ANT, the expression of CDK9 were markedly increased in breast
cancer tissues (Fig. 5A). Furthermore, the protein expression of
CDK9 in three delegated breast cancer tissues and ANT are showed
in Fig. 5B, which demonstrated a significantly higher protein
expression of CDK9 in breast cancer tissues compared with ANT.
3.6. Knockdown of CDK9 inhibits cell proliferation
To investigate the function of CDK9 in breast cancer cells lines,
CDK9 siRNA was transfected into MCF-7 and MDA-MB-231 cells.
As shown in Fig. 6A, CDK9 siRNA decreased 70% and 80% of the
expression of CDK9 in MCF-7 and MDA-MB-231 cells, respectively.
Colony formation and MTT assays were performed to assess the
effects of CDK9 on cell growth in vitro. Our data showed that rela-
tive cell growth was significantly inhibited in CDK9 siRNA transfec-
ted cells (Fig. 6B–D). As shown in Fig. 6E and F, our data
Fig. 4. miR-874 targets CDK9 to repress its expression. (A) Bioinformatic analysis using DIANA, miRDB, Targetscan, miRwalk and miRanda predicted that miR-874 may target
CDK9; (B) Putative miR-874 sites in the 30UTR region of CDK9 as determined by RNAhybrid program; (C) MCF-7 cells were transfected with miR-874 mimics to analyze the
effect on the luciferase intensity of pGL3/Luciferase–CDK9–30UTR reporter; (D) Real-time PCR and western blot assays were used to analyze the effect of miR-874 on CDK9
mRNA in MCF-7 and MDA-MB-231 cells.
Fig. 5. CDK9 levels in breast cancer tissues. (A) qRT-PCR was used to detect the expression of CDK9 in breast cancer tissues and adjacent normal tissues (ANT); (B) Western
blot was used to detect the expression of CDK9 in three pairs of breast cancer tissues and ANT.
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Fig. 6. Knockdown of CDK9 inhibits the cell proliferation and induces the cell apoptosis and cell cycle arrest in breast cancer cells. (A) Western blot was used to detect the
transfection efficiency of siRNA CDK9 in MCF-7 and MDA-MB-231 cells; (B) The long-term cell growth was determined by colony formation assay; (C and D) Cell survival was
determined by MTT assay; (E and F) The effect of siRNA CDK9 on cell apoptosis was detected using Annexin V-FITC/PI double staining method in MCF-7 and MDA-MB-231
cells by flow cytometry; (G and H) FACS was used to detect the effect of siRNA CDK9 on the cell cycle of MCF-7 and MDA-MB-231 cells.
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siRNA transfected MCF-7 and MDA-MB-231 cells (13.8% in miR-
control group vs. 33.6% in CDK9 siRNA group). Furthermore, we
demonstrated that we observed that knockdown of CDK9 by siRNA
lead to the cell cycle arrest in MCF-7 and MDA-MB-231 cells by
increasing the percentage of cells in G0/G1 phase and reducing
the cell population in the S phase (Fig. 6G and H).4. Discussion
Numerous studies have suggested the potential role of micro-
RNAs as oncogenic or tumor suppressive genes to cell cycle and
apoptosis via the regulation of different target genes in cancers
[23]. A set of miRNAs with differential expression levels and critical
tumor suppressive roles have been described in breast cancer cells,
4534 L. Wang et al. / FEBS Letters 588 (2014) 4527–4535including miR-145, miR-122a, miR-125a-5p, miR-126, miR-200c,
miR-10b, and miR-96 [24]. Furthermore, multivariate analysis in
breast cancer identified that downregulation of miR-155 and let-
7 expression were significantly correlated with a shorter patient
survival rate [25,26].
miR-874 is located on chromosome 5q31.2, a well-known fre-
quent fragile site in the human genome which is often deleted in
cancers and genetic disorders, and this site is also specifically cor-
related with chromosomal rearrangements in cancer [9]. A previ-
ous investigation has identified a significant loss of miR-874
expression in NSCLC tissue samples. Here, we determined the
miR-874 expression levels in breast cancer tissues and normal tis-
sues by Real-time PCR analysis, which displayed remarkable down-
regulation of miR-874 in the breast cancer tissues. Furthermore,
down-regulation of miR-874 were also observed in poor- or no-dif-
ferentiation tissues, and tissues with a tumor size greater than
5 cm. Thus, these results suggest the potential tumor suppressive
role of miR-874. And this was further confirmed by the experiment
in the breast cancer cell lines. Using breast cancer cell lines, MCF-7
and MDA-MB-231, we confirmed that overexpression of miR-874
decreased cell proliferation as determined by MTT and colony for-
mation assays. Furthermore, miR-874 overexpression significantly
suppressed tumor size in a time dependent manner in vivo.
Recently, an increasing number of studies have demonstrated
that the disregulation of miRNAs can exert its functions in cell
cycle progression and apoptosis in many human cancers. Research-
ers have identified that miR-15a can inhibit the cell cycle by target-
ing CCNE1 in breast cancer cells [27]. Functional assays revealed
that MCF-7 cells growth can be suppressed by miR-497 through
increasing the percentage of early apoptotic cells [28]. In this
study, we identified that overexpression of miR-874 significantly
increased the apoptosis of MCF-7 and MDA-MB-231 cells. Further-
more, we confirmed that miR-874 can induce cell cycle arrest.
In general, miRNAs exert its functions via binding to the 30UTR
of the target gene to repress its expression [29]. To identify the tar-
get genes of miR-874, bioinformatics analysis was performed via
different computational algorithms and CDK9 was screened as
our interest target gene. We then confirmed miR-874 had obvious
inhibiting effect on the luciferase intensity of CDK9–30UTR repor-
ter, whereas it had no further inhibiting effect on the CDK9–
30UTR-mut luciferase reporter, in which the miR-874 seed
sequence was mutated, which indicate that CDK9 is a direct target
for miR-874. Furthermore, miR-874 significantly suppressed the
protein level of CDK9 without affecting its mRNA level, indicating
that miR-874 can directly target the 30UTR of CDK9 mRNA, result-
ing CDK9 translation inhibition and suppressing its expression.
Recent studies have shown that the CDK9 is overexpressed in
several tumors compared with normal tissues [16]. Furthermore,
some of these studies have demonstrated that CDK9 can exhibitFig. 7. A proposed model of the miR-874/CDK9 axis in breast cancer tumorigenesis.anti-apoptotic effects or sustaining cell growth on several cancer
types [30]. In this study, our findings demonstrated that CDK9
expressed at higher levels in breast cancer tissues compared with
normal tissues. To further confirm that miR-874 can directly target
CDK9, the knockdown plasmid of CDK9 (siRNA CDK9) was used,
which demonstrate that siRNA CDK9 can suppress MCF-7 and
MDA-MB-231 cell lines proliferation. Furthermore, the knockdown
plasmid promoted cell apoptosis and induced cell cycle arrest,
which is consistent with the function of miR-874 overexpression.
In conclusion, the present study provides new insights into the
specific function of miR-874 and its mechanism in breast cancer
proliferation (Fig. 7), and suggests that targeting of miR-874 may
provide a potential therapeutic strategy for blocking proliferation
in breast cancer.Conflict of interests
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